KiroVAX 004

Drug Profile

KiroVAX 004

Alternative Names: KiroVAX-004; TAPA pulsed dendritic cell vaccine - KiroVAX-004

Latest Information Update: 17 Mar 2016

Price : $50

At a glance

  • Originator Kiromic
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 07 Mar 2016 Preclinical trials in Solid tumours (Metastatic disease, Treatment-resistant, Second-line therapy or greater) in USA (SC), before March 2016
  • 07 Mar 2016 Kiromic plans a phase I/II trial for Solid tumours in USA (NCT02705703)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top